Evolution of GLP-1RAs – From Breakthrough to Growth: Strategic Intelligence

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3450
Buy Report Download FREE Resources

Published: May 12, 2026 Report Code: GDHCHT723-TH

Select Item

GLP-1RA market report covering market growth, competitive landscape, dealmaking, obesity therapies, and future opportunities. Analyze the evolution of GLP-1 receptor agonists, benchmark leading companies, and support strategic decisions with GlobalData insights.

Understand the Evolution of the GLP-1RA Market

GLP-1 receptor agonists (GLP-1RAs) have evolved from therapies focused on type 2 diabetes (T2D) into one of the fastest-growing therapeutic classes. This report provides strategic insight into how GLP-1RAs have expanded beyond diabetes into obesity and other emerging indications, transforming the competitive landscape.

Originally developed to treat T2D, GLP-1 therapies have steadily broadened their clinical reach. The approval of obesity treatments marked a significant turning point, followed by expansion into additional therapeutic areas. As a result, the market has entered a new phase of sustained commercial growth and strategic investment.

Whether you are evaluating market opportunities, competitive positioning, or investment priorities, this report provides the insights needed to support informed decision-making.

Report Value Proposition – Why This Report Matters

This report goes beyond tracking market growth. It helps you understand the strategic forces shaping the future of GLP-1 therapies.

You can use this report to:

  • Assess growth opportunities across the evolving GLP-1RA market
  • Understand how the competitive landscape is changing
  • Benchmark against leading companies driving market expansion
  • Evaluate dealmaking activity, manufacturing investment, and partnership trends
  • Support portfolio planning, licensing, and business development strategies
  • Identify future growth opportunities beyond weight loss therapies

In addition, the report combines market intelligence with strategic analysis to help you understand not only where the market is today, but where it may be heading.

Key Insights into the GLP-1RA Market

The report provides comprehensive analysis across the major developments shaping this high-growth therapeutic market.

Key insights include:

  • The evolution of GLP-1 therapies from type 2 diabetes treatment into multi-indication therapies.
  • Significant sales growth from 2022 onwards, driven by newer obesity therapies.
  • Market expansion from approximately $53.7 billion in 2024 to a forecast of more than $182 billion by 2031.
  • Increasing investment through mergers, acquisitions, licensing agreements, manufacturing expansion, and strategic partnerships.
  • The changing basis of competition, where differentiation is increasingly focused on platform scalability, payer relevance, lifecycle expansion into new indications, and execution capabilities rather than weight loss efficacy alone.

Furthermore, the report explores the factors driving continued market momentum and the challenges companies should consider as competition intensifies.

Scope

What You Will Learn

The report provides detailed analysis across key areas of the GLP-1RA market, including:

  • GLP-1RA market momentum

  • Market size and long-term growth outlook

  • Competitive landscape and future market outlook

  • Dealmaking activity and strategic partnerships

  • Key market growth drivers

  • Case study examining the impact of GLP-1RA therapies in obesity

  • Executive summary and key strategic takeaways

Together, these insights provide a comprehensive view of how the GLP-1RA market is evolving and where future opportunities may emerge.

Target Buyers for This Report

This report is designed for professionals responsible for strategic decision-making across healthcare and life sciences, including:

  • Chief Strategy Officers

  • Commercial Strategy Leaders

  • Business Development and Licensing Teams

  • Market Intelligence Professionals

  • Pharmaceutical Portfolio Managers

  • Healthcare Investors and Equity Analysts

  • R&D Leadership Teams

  • Corporate Development Executives

  • Competitive Intelligence Teams

If you are responsible for identifying growth opportunities, evaluating competition, or shaping long-term strategy, this report can support your decision-making.

How Companies Use This Report

Organizations across the pharmaceutical and healthcare ecosystem can apply the findings in several practical ways.

  • Large pharmaceutical companies can evaluate competitive positioning, identify licensing opportunities, and assess long-term portfolio expansion strategies.

  • Biotechnology companies may use the report to understand where innovation opportunities exist and how competitors are approaching future indications.

  • Business development and licensing teams can monitor dealmaking activity, manufacturing investments, and partnership trends to support strategic decision-making.

  • Healthcare investors and financial institutions can assess market growth potential, competitive dynamics, and investment opportunities across the GLP-1 landscape.

  • Market intelligence and strategy teams can benchmark competitors, monitor emerging market trends, and support executive planning.

Key Highlights

GLP-1RA therapies have shifted from treating T2D to becoming multi-indication therapies. GLP-1RAs were originally developed for type 2 diabetes (starting with Byetta in 2005), and since 2014 they have expanded beyond T2D, beginning with obesity (Saxenda) and moving into additional indications.

GLP-1RA sales increased significantly from 2022 onwards, driven by newer therapies targeting obesity. This growth was fueled by the entry and rapid uptake of Mounjaro and Wegovy (Mounjaro grew from ~$0.5B in 2022 to ~$23B in 2025; Wegovy grew from ~$0.9B to ~$11B in 2025).

The GLP-1RA market is already large and forecast to grow substantially. The market was valued at ~$53.7B in 2024 and is forecast to reach over ~$182B by 2031.

Investment into GLP-1RAs continues to accelerate, with significant deals occurring yearly and manufacturing expanding to meet demand. Big pharma dealmaking (M&A and licensing) is increasing year-over-year, and companies are expanding manufacturing capacity through acquisitions, out-licensing, and partnership agreements.

The next phase of GLP-1RA competition will be about more than weight loss efficacy. Differentiation is moving beyond efficacy toward platform scalability, payer relevance, lifecycle expansion into new indications (e.g., CVD, MASH, and Alzheimer’s or Parkinson’s), and execution capability, while late-stage innovation remains scarce and the evidence bar continues to rise.

Reasons to Buy

Benchmark Against Market Leaders

Understanding how leading companies are positioning themselves is essential in a rapidly evolving market.

This report helps you benchmark against companies leading innovation and commercial success within GLP-1 therapies. Through competitive landscape analysis and real-world case studies, you can compare strategic priorities, market positioning, and growth approaches across the industry.

These insights may help support your own commercial, investment, and product development decisions.

Built on Trusted Data and Expert Analysis

GlobalData combines proprietary market intelligence with deep industry expertise to provide decision-ready insights.

This report is:

  • Built on GlobalData’s proprietary healthcare research and market intelligence

  • Trusted by Fortune 500 companies and leading government organizations

  • Backed by analysts with decades of healthcare and life sciences expertise

As a result, you gain reliable intelligence that can support strategic planning, investment evaluation, and competitive analysis.

Stay Ahead of the Next Phase of GLP-1 Competition

The GLP-1RA market is entering a new stage of competition. Growth is no longer driven solely by diabetes or obesity treatments. Instead, companies are expanding into additional indications while increasing investment in manufacturing, partnerships, and commercial capabilities.

Understanding these shifts early may help you identify emerging opportunities, benchmark against industry leaders, and make more informed strategic decisions.

Download the report today to gain a comprehensive view of one of healthcare’s fastest-growing therapeutic markets.

Table of Contents

Executive Summary

Introduction

GLP-1RA Market Momentum

Market Size and Growth

Competitive Landscape & Market Outlook

Dealmaking

Growth Drivers

Case Study: The Impact of GLP-1RA in Obesity

Key Takeaways

Evolution of GLP-1RAs – From Breakthrough to Growth: Strategic Intelligence thematic reports
Currency USD
$3,450

Can be used by individual purchaser only

Most Popular
$6,900

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,350

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Evolution of GLP-1RAs – From Breakthrough to Growth: Strategic Intelligence was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Services reports
Pharmaceuticals
New
Emerging Market Outsourcing Report, Q2 2026
$2,950 | July 2026
Pharmaceuticals
New
Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive…
$3,495 | July 2026
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Evolution of GLP-1RAs – From Breakthrough to Growth: Strategic Intelligence in real time.

  • Access a live Evolution of GLP-1RAs – From Breakthrough to Growth: Strategic Intelligence dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more